CereVasc Raises $85 Million in Series C Funding
CereVasc, a Boston-based medical technology company, has successfully closed an $85 million Series C funding round. The company focuses on improving patient outcomes for those suffering from communicating hydrocephalus through its innovative eShunt® device.
Key Investors and Lead Investor
The funding round was led by Piper Sandler Merchant Banking. Other significant participants in this round include Johnson & Johnson Innovation, Medtronic, Bain Capital Life Sciences, and Perceptive Xontogeny Venture Funds. This diverse group of investors highlights the growing interest and confidence in CereVasc's approach to treating hydrocephalus.
About CereVasc
CereVasc is dedicated to redefining the treatment landscape for communicating hydrocephalus. The company’s flagship product, the eShunt® device, is designed to offer a less invasive and potentially more effective solution for patients. By focusing on this niche yet impactful area of medical treatment, CereVasc aims to make significant strides in improving quality of life for those affected by the condition.
Strategic Use of Funds
While specific plans for the use of the newly acquired funds have not been disclosed in detail, it is expected that CereVasc will channel this capital towards further development and commercialization of the eShunt® device. Investments in research and development, as well as potential expansion into new markets, could be on the horizon as the company seeks to solidify its position in the medical device industry.
Conclusion
The successful closing of this Series C round marks a pivotal moment for CereVasc as it continues to innovate in the field of hydrocephalus treatment. With the backing of prominent investors and a clear focus on improving patient outcomes, CereVasc is well-positioned to advance its mission and bring new solutions to the market.